SWOG S0226: A Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First Line Therapy for Post Menopausal Women With Metastatic Breast Cancer.

Trial Profile

SWOG S0226: A Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First Line Therapy for Post Menopausal Women With Metastatic Breast Cancer.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Jan 2018

At a glance

  • Drugs Fulvestrant (Primary) ; Anastrozole
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 09 Dec 2017 Results assessing progression-free survival and overall survival otucomes (five years after the initial positive findings), presented at the 40th Annual San Antonio Breast Cancer Symposium.
    • 06 Dec 2017 Planned End Date changed from 1 Oct 2017 to 1 Oct 2018.
    • 15 Feb 2017 Planned End Date changed from 1 Oct 2014 to 1 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top